HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Eton Pharmaceuticals (NASDAQ:ETON) and maintained a $10 price target on the stock.
December 11, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Eton Pharmaceuticals and maintains a $10 price target.
The reiteration of a Buy rating and the maintenance of a $10 price target by a reputable analyst could instill confidence in investors and positively influence Eton Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100